• Kazia Therapeutics director Ebru Davidson filed an initial Form 3 disclosing ADS options covering 77,000 shares with exercise prices of $0.33 and $8.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-256067), on June 03, 2026, and is solely responsible for the information contained therein.